Drug Safety Board Is Biased By Connection To CDER, Sen. Grassley Says
This article was originally published in The Tan Sheet
Executive Summary
Sen. Charles Grassley (R-Iowa) is asking FDA to outline what actions the agency will take to ensure that the Drug Safety Oversight Board is "objective.